Background
Methods
Study design
Patients
Inclusion criteria
Exclusion criteria
Specimen characteristics
Survival data
Immunohistochemistry (IHC)
Evaluation of immunohistochemical staining
Statistical analyses
Results
Study subjects (N = 317) |
N
|
Normal | 105 |
Dysplasia | 97 |
OSCC | 115 |
Dysplasia (N = 97) |
N (%) |
Age years (range, median) | 30–88, 60 |
Gender | |
Male | 51 (53 %) |
Female | 46 (47 %) |
Follow-up outcome | |
Positive | 22 (23 %) |
Negative | 61 (63 %) |
Data not available | 14 (14 %) |
OSCC (n = 115) | |
Age years (range, median) | 30–92, 61 |
Sex | |
Male | 73 (63 %) |
Female | 42 (37 %) |
AJCC pTNM classification | |
I | 21 (18 %) |
II | 19 (17 %) |
III | 23 (20 %) |
IV | 35 (30 %) |
Unknown | 17 (15 %) |
Extra capsular invasion | |
Positive | 18 (16 %) |
Negative | 97 (84 %) |
Perineural involvement | |
Positive | 33 (29 %) |
Negative | 82 (71 %) |
Vascular involvement | |
Positive | 16 (14 %) |
Negative | 99 (86 %) |
Follow-up outcome | |
Positive | 32 (28 %) |
Negative | 61 (53 %) |
Data not available | 22 (19 %) |
Immunohistochemical analysis of Ep-ICD and EpEx expression in oral tissues
Comparison with normal tissues | Comparison with dysplastic tissues | ||||||||
---|---|---|---|---|---|---|---|---|---|
N
|
n
| % |
p-value | O.R | 95 % C.I. |
p-value | O.R | 95 % C.I. | |
Ep-ICD Nuclear | |||||||||
Normal | 105 | 38 | 36.19 | ||||||
Dysplasia | 97 | 52 | 53.61 | 0.013 | 2.037 | 1.16–3.58 | |||
OSCC | 115 | 98 | 85.22 | <0.001 | 10.164 | 5.30–19.49 | <0.001 | 4.99 | 2.60–9.57 |
Ep-ICD Cyto | |||||||||
Normal | 105 | 87 | 82.86 | ||||||
Dysplasia | 97 | 81 | 83.51 | 0.90 | 1.05 | 0.50–2.19 | |||
OSCC | 115 | 92 | 80 | 0.59 | 0.83 | 0.42–1.64 | 0.512 | 0.79 | 0.39–1.60 |
EpEX membrane | |||||||||
Normal | 105 | 15 | 14.29 | ||||||
Dysplasia | 97 | 37 | 38.14 | <0.001 | 3.70 | 1.87–7.33 | |||
OSCC | 115 | 28 | 24.35 | 0.06 | 1.93 | 0.97–3.86 | 0.03 | 0.52 | 0.29–0.94 |
Comparison with normal tissues | Comparison with dysplastic tissues | ||||||||
---|---|---|---|---|---|---|---|---|---|
N
|
n
| % |
p-value | O.R | 95 % C.I. |
p-value | O.R | 95 % C.I. | |
Ep-ICD Nuclear | |||||||||
Normal | 105 | 38 | 36.19 | ||||||
Dysplasia | 97 | 52 | 53.61 | 0.013 | 2.037 | 1.16–3.58 | |||
OSCC | 115 | 98 | 85.22 | <0.001 | 10.164 | 5.30–19.49 | <0.001 | 4.99 | 2.60–9.57 |
Ep-ICD Cyto | |||||||||
Normal | 105 | 87 | 82.86 | ||||||
Dysplasia | 97 | 81 | 83.51 | 0.90 | 1.05 | 0.50–2.19 | |||
OSCC | 115 | 92 | 80 | 0.59 | 0.83 | 0.42–1.64 | 0.512 | 0.79 | 0.39–1.60 |
EpEX membrane | |||||||||
Normal | 105 | 15 | 14.29 | ||||||
Dysplasia | 97 | 37 | 38.14 | <0.001 | 3.70 | 1.87–7.33 | |||
OSCC | 115 | 28 | 24.35 | 0.06 | 1.93 | 0.97–3.86 | 0.03 | 0.52 | 0.29–0.94 |
Prognostic analysis of Ep-ICD and EpEx in oral dysplasia and OSCC patients
OSCC | Kaplan-Meier survival analysis unadjusted p-value | Multivariate Cox regression analysis adjusted p-value | Hazard’s ratio (H.R.) | 95 % C.I. |
---|---|---|---|---|
Ep-ICDNuc
+
| 0.078 | 0.049 | 0.35 | 0.12–0.98 |
EpExMembrane
+
| 0.302 | 0.189 | ---- | ---- |
Ep-ICDNuc + EpExMembrane
+
|
0.016
|
0.003
|
4.01
|
1.64–9.83
|
Age | 0.33 | 0.026 | ---- | ---- |
T classification | 0.63 | 0.913 | ---- | ---- |
Nodal classification |
0.041
| 0.633 | ---- | ---- |
Clinical stage | 0.225 | 0.293 | ---- | ---- |
Extra capsular invasion |
<0.001
|
0.004
|
4.14
|
1.56–10.96
|
Perineural involvement | 0.828 | 0.102 | ---- | ---- |
Vascular involvement | 0.355 | 0.552 | ---- | ---- |